Regeneron Priced Otarmeni at Zero — And That’s the Most Expensive Move in Ultra-Rare Disease This Decade
Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...
Coultreon’s $125M Bet Proves the Real Alpha in Biotech Is Knowing Which Shipwrecks Are Worth Salvaging
Coultreon Biopharma raised $125M Series A for rescued Galapagos oncology assets — and the investor syndicate tells you exactly...
China’s Drug Machine Is Handing Western Pharma a Strategic Crisis Disguised as a Partnership Opportunity
China now drives first-in-class innovation, not just generics—and every Western pharma BD team underpricing that shift is building a...
Medtronic’s $100M Bet on Pulnovo Isn’t About Pulmonary Hypertension — It’s About Owning the Next Cardiovascular Platform
Medtronic's strategic investment in Pulnovo Medical's oversubscribed $100M round signals a quiet land grab in pulmonary hypertension and heart...
BioNTech’s Endometrial ADC Data Is Not a Science Story — It’s a $3 Billion Market Access Problem in Disguise
Trastuzumab pamirtecan just posted compelling Phase 2 numbers in HER2-expressing recurrent endometrial cancer. The science is clean. The commercial...
Oricell’s $110 Million Bet Exposes the Dirty Secret of Solid Tumor CAR-T: The Science Is Ahead of the Business Model
Oricell Therapeutics just closed a $110 million pre-IPO round to push its CAR-T platform into solid tumors. Investors are...
Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible
A bispecific nanobody hitting primary endpoints in both asthma and CRSwNP phase 2 trials isn't just a pipeline win...
Novo Nordisk’s Patent Cliff Isn’t Coming — It’s Already Here, and the Pricing Model Breaks on Impact
Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...
Novo Nordisk’s Hims & Hers Deal Isn’t a Distribution Play — It’s a Controlled Burn of Its Own Pricing Floor
Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...
Pfizer’s R&D Reset Isn’t a Strategy — It’s a Symptom of Something Bigger
Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...